Alphatec Spine Announces Participation at the Oppenheimer & Co. Inc. 28th Annual Healthcare Conference
March 19 2018 - 9:00AM
Alphatec Holdings, Inc. (“Alphatec” or the “Company”)
(Nasdaq:ATEC), a provider of innovative spine surgery solutions
with a mission to improve patient lives through the relentless
pursuit of superior outcomes, today announced it will present at
the 28th Annual Oppenheimer & Co. Inc. Healthcare Conference on
March 21, 2018, at 1:35 P.M. EDT at The Westin New York Grand
Central.
Terry Rich, President and Chief Operating
Officer of Alphatec, will provide an overview of the Company's
business during the live presentation. Management will also
be available to participate in one-on-one meetings with investors
who are registered to attend the conference.
A copy of the presentation will be available
online from the investor relations page of the Company's corporate
website at www.atecspine.com. The conference will be webcast
live. To access the webcast, please visit
https://www.veracast.com/webcasts/opco/healthcare2018/29213570882.cfm.
The webcast replay will remain available for 90 days
following the live presentation.
About Alphatec
Alphatec Holdings, Inc., through its wholly
owned subsidiary Alphatec Spine, Inc., is a medical device company
that designs, develops, and markets spinal fusion technology
products and solutions for the treatment of spinal disorders
associated with disease and degeneration, congenital deformities,
and trauma. The Company's mission is to improve lives by providing
innovative spine surgery solutions through the relentless pursuit
of superior outcomes. The Company markets its products in the U.S.
via independent sales agents and a direct sales force.
Additional information can be found at
www.atecspine.com.
Forward-Looking Statements
Statements made in this press release and made
during the investor events referenced herein may contain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 that involve risks and
uncertainty. Such statements are based on management's current
expectations and are subject to a number of risks and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements.
These and other forward-looking statements are
not guarantees of future results and are subject to risks,
uncertainties and assumptions that could cause actual results to
differ materially from those expressed in any forward-looking
statements. Forward-looking statements by their nature address
matters that are, to different degrees, uncertain.
Forward-looking statements include the references to the Company’s
strategy in significantly repositioning the Alphatec brand and
turning the Company into a growth organization. The important
factors that could cause actual operating results to differ
significantly from those expressed or implied by such
forward-looking statements include, but are not limited to: the
uncertainties regarding the Company’s ability to recognize the
expected synergies and other benefits of the SafeOp acquisition;
the difficulties in the integration of SafeOp post-closing; the
diversion of management time to address transaction-related issues;
the uncertainties related to litigation involving the acquisition
of SafeOp or the 2018 private placement or limitations or
restrictions imposed by regulatory authorities; the uncertainties
related to unanticipated integration costs or undisclosed
liabilities assumed; the uncertainties related to the acceptance of
the SafeOp acquisition and its products by third parties; the
uncertainty of success in developing new products or products
currently in the Company’s pipeline; the uncertainties in the
Company’s ability to execute upon its strategic operating plan; the
uncertainties regarding the ability to successfully license or
acquire new products, and the commercial success of such products;
failure to achieve acceptance of the Company’s products by the
surgeon community, including Battalion and Arsenal Deformity;
failure to obtain FDA or other regulatory clearance or approval for
new products, or unexpected or prolonged delays in the process;
continuation of favorable fourth party reimbursement for procedures
performed using the Company’s products; unanticipated expenses or
liabilities or other adverse events affecting cash flow or the
Company’s ability to successfully control its costs or achieve
profitability; uncertainty of additional funding; the Company’s
ability to compete with other competing products and with emerging
new technologies; product liability exposure; an unsuccessful
outcome in any litigation in which the Company is a defendant;
patent infringement claims; claims related to the Company’s
intellectual property and the Company’s ability to meet its
financial obligations under its credit agreements and the Orthotec
settlement agreement. A further list and description of these
and other factors, risks and uncertainties can be found in the
Company’s most recent annual report, and any subsequent quarterly
and current reports, filed with the Securities and Exchange
Commission. Alphatec disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise, unless
required by law.
Investor/Media Contact:
Lee Roth / Emma PoalilloThe Ruth Group(646)
536-7000alphatec@theruthgroup.com
Company Contact:
Jeff BlackExecutive Vice President and Chief Financial
OfficerAlphatec Holdings, Inc. ir@atecspine.com
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Apr 2023 to Apr 2024